Evidence map›Paper›PMID 40431609›Full record

ArticleViruses2025

A Novel Toolkit of SARS-CoV-2 Sub-Genomic Replicons for Efficient Antiviral Screening.

Maximilian Erdmann, Peter A C Wing, Isobel Webb, Maia Kavanagh Williamson, Tuksin Jearanaiwitayakul, Edward Sullivan, James Bazire, Iart Luca Shytaj, Jane A McKeating, David A Matthews and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maximilian ErdmannSchool of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK.ORCID 0000-0003-2084-9792
Peter A C WingChinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford OX3 7BN, UK.
Isobel WebbSchool of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK.
Maia Kavanagh WilliamsonSchool of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK.ORCID 0000-0002-4659-8613
Tuksin JearanaiwitayakulSchool of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK.ORCID 0000-0002-2555-8516
Edward SullivanSchool of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK.
James BazireSchool of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK.
Iart Luca ShytajSchool of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK.
Jane A McKeatingChinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford OX3 7BN, UK.ORCID 0000-0002-7229-5886
David A MatthewsSchool of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK.ORCID 0000-0003-4611-8795
Andrew D DavidsonSchool of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK.

Funding

Chinese Academy of Medical Sciences, Innovation Fund for Medical Science 2018I2M-2-002Medical Research Council MR/R020566/1Medical Research Council MR/V027506/1; MR/R020566/1; MR/W005611/1/; MR/Y004205/1Medical Research Council MR/W005611/1/Medical Research Council MR/Y004205/1United States Food and Drug Administration 5F40120C00085Wellcome Trust 200838/Z/16/ZWellcome Trust 794 204813/Z/16/ZWellcome Trust 794 204813/Z/16/Z; 200838/Z/16/Z
6 · The paper itself

Abstract

SARS-CoV-2 is classified as a containment level 3 (CL3) pathogen, limiting research access and antiviral testing. To address this, we developed a non-infectious viral surrogate system using reverse genetics to generate sub-genomic replicons. These replicons contained the nsp1 mutations K164A and H165A and had the spike, membrane, ORF6, and ORF7a coding sequences replaced with various reporter and selectable marker genes. Replicons based on the ancestral Wuhan Hu-1 strain and the Delta variant of concern were replication-competent in multiple cell lines, as assessed by

Indexed as

Antiviral AgentsRepliconSARS-CoV-2AnimalsCell LineChlorocebus aethiopsCOVID-19 Drug TreatmentDrug Evaluation, PreclinicalGenome, ViralHumansMutationReverse GeneticsVero CellsViral Nonstructural ProteinsVirus ReplicationAntiviral AgentsViral Nonstructural ProteinsantiviralRNA repliconSARS-CoV-2SARS-CoV-2 nsp1

Identifiers

PMID40431609
PMCPMC12115450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.